Regenosine is developing a disease-modifying regenerative therapy for osteoarthritis.
Regenosine has raised $25K in total funding. The most recent round was Grant. The last funding was announced in February 2023.
Regenosine's investors include Creative Destruction Lab, NJEDA, SeedFolio, NIAMS.
Regenosine is headquartered in New Jersey, Trinidad and Tobago.
Regenosine is developing a disease-modifying regenerative therapy for osteoarthritis.
Regenosine is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Regenosine — Funding & Investors." VCBacked, February 16, 2023, https://www.vcbacked.co/company/regenosine. Accessed August 13, 2026.
VCBacked. (2023). Regenosine — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/regenosine
{{cite web |title=Regenosine — Funding & Investors |url=https://www.vcbacked.co/company/regenosine |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated